Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial by Akio Koyama et al.
RESEARCH ARTICLE Open Access
Orally active prostacyclin analogue beraprost
sodium in patients with chronic kidney disease:
a randomized, double-blind, placebo-controlled,
phase II dose finding trial
Akio Koyama1*, Toshiro Fujita2, Fumitake Gejyo3, Hideki Origasa4, Masanao Isono5, Hajimu Kurumatani5,
Kiyonobu Okada5, Hiroyuki Kanoh6, Takashi Kiriyama6 and Shunsuke Yamada6
Abstract
Background: Evidence increasingly points to the importance of chronic hypoxia in the tubulointerstitium as a final
common pathway to end-stage renal disease (ESRD). Beraprost sodium (BPS) is an orally active prostacyclin (PGI2)
analogue demonstrating prevention of the progression of chronic kidney disease (CKD) in various animal models by
maintaining renal blood flow and attenuating renal ischemic condition.
Methods: This multicenter, randomized, double-blind, placebo-controlled, phase II trial was designed to determine
the recommended dose of the sustained-release form of BPS (TRK-100STP 120 μg/day or 240 μg/day) in Japanese
patients with CKD. TRK-100STP was administered to a total of 112 patients. The primary efficacy endpoint was the
difference in the slope of the regression line of reciprocal of serum creatinine (1/SCr) over time, obtained by the
least-squares method.
Results: Regarding the primary endpoint, statistical superiority of TRK-100STP 240 μg over placebo was not
confirmed and so a recommended dose was not determined. Compared to placebo, however, the slope of
regression line of 1/SCr, elevation of SCr and serum cystatin C during the treatment period revealed greater
improvement at 120 μg, at both doses, and at 240 μg, respectively. In terms of safety, both TRK-100STP treatment
groups were well tolerated.
Conclusions: Although the study failed to meet the primary endpoint, results indicate that TRK-100STP may
potentially prevent the decline in renal function of CKD patients independent of blood pressure or urinary
protein levels.
Trial registration: NCT02480751. June 21, 2015.
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Background
An increasing number of patients with end-stage renal dis-
ease (ESRD) require dialysis or transplantation. Although
diabetic nephropathy is a major reason for eventual ESRD,
primary glomerular diseases and nephrosclerosis still com-
prise significant proportions of chronic kidney disease
(CKD) patients, especially in Asian countries [1–4].
Angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin-II receptor blockers (ARBs) are often adminis-
tered to both diabetic and non-diabetic nephropathy pa-
tients, and are established as recommended treatment
agents for non-diabetic nephropathy patients with albu-
min excretion [5]. However, it is evident that these agents
are insufficient for the prevention of progressive renal
disease. In addition, the use of combination therapy of
renin-angiotensin system (RAS) inhibitors such as ACEI
and ARB has demonstrated in some recent clinical trials
to be not effective [6–9]. These findings suggest an urgent
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clinical need for a new treatment option able to signifi-
cantly delay the progression of CKD.
Prostacyclin (PGI2) is primarily synthesized in endothelial
cells and one of the important functions is to protect kid-
neys from ischemic damage in pathophysiological condi-
tions [10], as evidenced, for example, by the development
of renal impairment in prostacyclin synthase knockout
mice [11]. Attempts have been made to use PGI2 or its ana-
logues in patients with kidney disease; the PGI2 analogue
iloprost was successfully used for patients with contrast
media-induced nephropathy [12].
Beraprost sodium (BPS) is an orally active PGI2
analogue [13] and TRK-100STP is its sustained-release
form [14]; both were generated and developed by Toray
Industries, Inc. In Asian countries, the immediate-
release form of BPS has been widely used in the treat-
ment of patients with chronic arterial occlusion and pul-
monary arterial hypertension [15].
Recent evidence increasingly points to the importance
of chronic hypoxia especially in the tubulointerstitium
as a final common pathway to the progression of CKD
[16–20]. BPS prevents the progression of CKD in vari-
ous animal models [21–24] by maintaining renal micro-
vasculature and blood flow [25, 26]. In addition, it is
reported that BPS is effective in Acute Kidney Injury
such as contrast nephropathy and cisplatin nephropa-
thy [27, 28]. These effects of BPS are thought to be
based on multiple mechanisms of actions: direct pro-
tective effect on vascular endothelial cells [29]; inhib-
ition of the production of inflammatory cytokines from
monocyte/macrophages [23]; vasodilative [30] and anti-
platelet effects [31]. The effects of BPS have also been
assessed in two studies in patients with glomerulonephritis
[32, 33]. Although these studies were open-label and did
not have control group, the results of one study suggested
that BPS mitigates the progression rate of renal dys-
function [32, 33] by increasing renal blood flow without
glomerular hyperfiltration.
The efficacy of BPS on diabetic nephropathy has also
been reported in several clinical [34] and non-clinical
studies [35–37]; however, several methodological limita-
tion are evident with regards to the involvement of both
diabetic and non-diabetic CKD patients in a single proto-
col. Given the evident unmet need for non-diabetic ne-
phropathy treatment in Asia and considering that much
of the non-clinical data on BPS has been generated in
non-diabetic CKD, the priority and focus of the present
study was on non-diabetic CKD, given that renal disorders
are not modified by diabetes. This is the first randomized,
placebo-controlled, double-blind, comparative trial to in-
vestigate the recommended dose at which TRK-100STP
suppresses the progression of CKD in patients with pri-
mary glomerular disease or nephrosclerosis.
Methods
This multicenter, randomized, double-blind placebo-
controlled, phase II trial was designed to determine the
recommended dose of TRK-100STP (i.e., either 120 μg/day
or 240 μg/day) for suppressing progression in Japanese
patients with primary glomerular disease or nephrosclero-
sis. The study was approved by each participating center’s
local Research Ethics Committee. Only patients with
written informed consent were included (Please refer to
the list of participating centers at the end of the paper).
Study design
A summary of the study method is presented in Fig. 1.
After the run-in period, when placebo tablets were orally
Fig. 1 Summary of study design
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Fig. 2 Inclusion and exclusion cliteria
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administered twice daily for 22 weeks in a single-blinded
manner, patients who met all of the inclusion criteria and
none of the exclusion criteria (detailed in Fig. 2) were
randomized into one of the three treatment groups (TRK-
100STP 120 μg, 240 μg or placebo group) using computer
random number generator to select random permuted
blocks. Central randomization was performed by external
statistician for the 28-week treatment period in a double-
blinded manner. Enrollment to the trial was restricted to
patients whose renal function had progressively declined
during the 22-week run-in period (R0 ~ R20) to obtain
adequate treatment response data during the 28-week
treatment period (W0 ~W28).
Reciprocal of serum creatinine (1/SCr) versus time slope
shows the speed of renal function decline so that this
parameter is used to estimate how long it will take to start
dialysis and to evaluate therapeutic effects [38]. This par-
ameter is used for example to show the status of nephrop-
athy in the RENAAL trial [39].
Therefore, in order to limit the participants to those
with progressive diseases, only patients whose recipro-
cal of serum creatinine (1/SCr) versus time slope
was ≤ −0.005 dL/mg over 4 weeks during the run-in
period were randomized. This value was based on the
patients’ background in a trial of orally administered
spherical carbon adsorbent AST-120 [40]. The primary
endpoint was also 1/SCr versus time slope and the differ-
ences between the treatment- and the observation-period
values were evaluated.
The study drug in the treatment period was orally
administered twice daily, after meals, for 28 weeks in a
double-blinded manner. The first 2 weeks of the treat-
ment period were designated as the dose-titration
period with respect to safety analyses. The initial dose
for the TRK-100STP groups was 120 μg/day. For the
240 μg group, the dose was increased to 240 μg/day
after the 2-week dose-titration period. One follow-up
assessment was performed between 7 to 35 days after
completion or discontinuation of study drug during the
treatment period.
The two doses of TRK-100STP (120 μg/day and
240 μg/day) were selected for this trial on the basis that
a 30 μg single dose was considered unable to achieve
the effective plasma concentration, whilst a 180 μg
single dose previously resulted in a higher incidence of
headache and other adverse drug reactions (ADRs) in a
completed phase I clinical study of TRK-100STP. Based
on these observations, TRK-100STP at 60 to 120 μg
b.i.d. (i.e., 120 to 240 μg/day) were selected for investi-
gation in the present trial.
Study endpoints
The primary efficacy endpoint was the difference between
the run-in and treatment periods in the slope of the re-
gression line of 1/SCr versus time, which was calculated
by the least-squares method. All SCr data collected in
the run-in period (R0 ~ R20) and the treatment period
(W4 ~W28) were used for the plot in order to exclude
the possible effect of the titration period (W0 ~W2).
Secondary endpoints were as follows: 1) The difference
between the run-in period (R0 ~ R20) and treatment
period (W0 ~W28) in 1/SCr versus time slope; 2) changes
in creatinine clearance (CCr, Cockcroft-Gault equation);
3) changes in CCr (urinalysis with 24-hour pooled urine);
4) changes in urinary protein excretion; 5) ratio of SCr;
and 6) changes in serum cystatin C. Safety endpoints were
as follows: 1) adverse events (AEs); 2) clinical laboratory
tests; 3) vital signs and body weight; and 4) 12-lead elec-
trocardiogram (ECG).
Prohibited and restricted concomitant medications
Prohibited concomitant medications
Use of the following medications were prohibited during
the study period: spherical carbon adsorbent; prostaglandin
Table 1 Study measurements
Examination by investigator Objective symptoms (patient interview)
Physical examination Body weight, blood pressure, pulse rate, 12-lead ECG
Hematological examination WBC, RBC, Hb, Ht, PLT,
Differential count of leukocytes (basophil, eosinophil, neutrophil, lymphocyte, monocyte)
Bleeding and coagulation test PT, APTT
Blood biochemistry TP, Alb, T-BIL, AST(GOT), ALT(GPT), ALP, LDH, γ-GTP,
TCh, TG, UA, BUN, serum creatinine (SCr), Na, K, Cl, Ca, P, HbA1c, cystatin C,
High-sensitive CRP
Uremia toxins test in plasma Guanidino succinate
Urinalysis (occasional urine) pH, qualitative protein, glucose, and urobilinogen, occult blood reaction urinary sediment (RBC, WBC, casts),
β2 microglobulin (adjusted by creatinine), pregnancy test (hCG)
Urinalysis (24-hour pooled urine) Urinary protein excretion, CCr, urea nitrogen, electrolytes (Na, Cl), urine output, creatinine
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Fig. 3 (See legend on next page.)
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analogues, other than eye drops and those in ointment
form; antiplatelet agents, with the exception of aspirin
products; anticoagulant and thrombolytic agents, except
for temporary use such as for examinations; fluorinated
pyrimidine antifungal agents; and iodinated radiocontrast
agents.
Restricted concomitant medications
Dosage of ACEIs and ARBs were stipulated to be fixed
during the study period. However, in necessary situa-
tions, such as increased serum potassium levels that did
not improve with alternative options, a reduction in
ACEI or ARB doses was allowed. Taking nonsteroidal
anti-inflammatory drugs (NSAIDs) continuously for more
than one week was prohibited.
Sample size estimation
The sample size estimation was based on a previous
study, a Phase III clinical trial of AST-120 (indicated
for the treatment of chronic renal failure (CRF) in
Japan), conducted in a total of 237 patients (119 pa-
tients treated with the active drug and 118 received pla-
cebo) for 24 weeks [40]. The study showed that the
difference in the slope of regression line of 1/SCr ver-
sus time of AST-120 and the placebo groups before and
after treatment with the test drug was 0.00352 (dL/mg
over 4 weeks). Based on this value, we hypothesized
that the TRK-100STP 120 μg group would show effi-
cacy similar to the AST-120 group, and that the TRK-
100STP 240 μg group would show 1.5 times better
efficacy than the AST-120 group. According to these
predictions, we set contrast coefficients [−1, 0, 1] for
the placebo, the TRK-100STP 120 μg, and the 240 μg
groups. The number of patients required per group was
estimated to be 71 (with a two-sided 5 % significance
level and 80 % statistical power). On this basis, the tar-
get number of patients needed to recruit was set at 430
patients, taking into account the possibility that the pa-
tient withdrawal rate in the run-in period might be high
because of the long run-in period.
Statistical analysis
(a) Primary endpoint
Using all SCr data collected during the run-in period
(R0 ~ R20) and treatment period (W4 ~W28), recipro-
cal SCr values plotted against time were analyzed. The
slopes of the regression line were calculated by applying
the least-squares equation. The difference in the slopes
between the run-in period (R0 ~ R20) and treatment
period (W4 ~W28) was evaluated as the primary end-
point. In order to determine the recommended dose,
Table 2 Baseline characteristics of patients in the full analysis set (FAS)
Parameter Treatment group
Placebo 120 μg 240 μg
(n = 34) (n = 32) (n = 36)
Sex Male 18 (52.9 %) 17 (53.1 %) 24 (66.7 %)
Female 16 (47.1 %) 15 (46.9 %) 12 (33.3 %)
Age Mean ± SD (years) 59.9 ± 10.0 56.5 ± 14.7 57.8 ± 13.9
Primary disease Primary glomerular disease 28 (82.4 %) 27 (84.4 %) 25 (69.4 %)
Nephrosclerosis 6 (17.6 %) 5 (15.6 %) 11 (30.6 %)
1/SCr time slope during the run-in period Mean ± SD (dL/mg over 4 weeks) −0.01210 ± 0.00497 −0.01535 ± 0.00808 −0.01198 ± 0.00788
SCra Mean ± SD (mg/dL) 2.377 ± 0.665 2.251 ± 0.618 2.564 ± 0.705
Urinary protein excretiona Mean ± SD (mg/day) 2103.7 ± 1523.0 2037.5 ± 1763.4 1753.9 ± 1396.2
Systolic blood pressurea Mean ± SD (mmHg) 122.7 ± 16.1 129.0 ± 13.3 129.4 ± 15.6
Diastolic blood pressurea Mean ± SD (mmHg) 72.5 ± 11.0 73.4 ± 10.3 75.1 ± 10.6
Concomitant medication ACEI (+) 13 (38.2 %) 9 (28.1 %) 12 (33.3 %)
ACEI/ARB positive ARB (+) 25 (73.5 %) 26 (81.3 %) 25 (69.4 %)
aAs of R20
(See figure on previous page.)
Fig. 3 Patient dispositiona. aCONSORT 2010 flow diagram was provided as Additional file 1. * The number of the patients who were excluded
during the Run-in period (n = 279) was calculated by adding the number of the patients who dropped out during the Run-in period (n = 278)
and the patient who was excluded before the initiation of the study treatment (n = 1). ** Ten patients whose SCr values measured less than
three points after Week 4 of the Treatment period were excluded from 112 patients randomized. As a results, 102 patients (32 patients in the 120
μg group, 36 patients in the 240 μg group and 34 patients in the placebo group) were included in the full analysis set (FAS). *** If there were
multiple reasons for discontinuation, the main reason was used for calculation
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the primary endpoint was analyzed by the following
procedures:
 Step 1: Analysis of covariance (ANCOVA) with the
slopes calculated from the results obtained during
the run-in period as a covariate after assigning
contrast coefficients [−1, 0, 1].
 Step 2: ANCOVA with the slopes obtained from
the results collected during the run-in period as a
covariate after assigning contrast coefficient [−1, 1, 0],
only when a statistical significance was detected in
Step 1.
(b) Secondary endpoints
Analytical methods for secondary endpoints are de-
scribed in each result.
(c) Post hoc analysis
Ratio of SCr (the final evaluation point/W0)
In analyzing the ratio of SCr for the secondary endpoint,
the SCr values measured at R20 were chosen as baseline
as other parameters such as CCr, urinary protein and
cystatin C were measured only at R20. Regarding SCr,
however, as the value at W0 measured just before the
treatment period was available, the ratio of SCr (the final
evaluation point/W0) was assessed by ANCOVA with the
SCr (R20) as covariate.
Change in serum cystatin C in the treatment period
(final evaluation point - R20)
As the ratio of SCr was analyzed only for the treatment
period, changes in cystatin C were re-evaluated based only
on data from the treatment period.
Changes in cystatin C were calculated using values
taken at R20 as the baseline (the final evaluation point –
R20). ANCOVA was performed with the SCr (R20) as the
covariate. As the values at W0 were not available, the
values at R20, the examination point of the study closest
to W0, were used as baseline.
Ratio of eGFR (the final evaluation point/W0)
Ratio of eGFR (the final evaluation point/W0) was
assessed by ANCOVA with the SCr (R20) as covariate.
In order to calculate the eGFR for Japanese patients,
the following equation was used;
GFR(male) = 194*Scr-1.094*age-0.287, and GFR(female) =
GFR(male)*0.739 [41].
Study measurements
The parameters that were measured and analyzed are
listed in Table 1.
Table 3 Summary statistics of primary endpoint (the difference in the 1/SCr versus time slope between run-in period [R0 ~ R20] and
treatment period [W4 ~W28])
Treatment group No. of patients 1/SCr versus time slope (dL/mg over 4 weeks) Difference in the 1/SCr versus
time slope (dL/mg over 4 weeks)
Run-in period (R0 ~ R20) Treatment period (W4 ~W28)
Mean SD Mean SD Mean SD
Placebo 34 −0.0121 0.00497 −0.0074 0.00935 0.0047 0.01087
120 μg 32 −0.0154 0.00808 −0.0040 0.01345 0.0113 0.01011
240 μg 36 −0.0120 0.00788 −0.0045 0.00750 0.0075 0.00953
Fig. 4 Change in SCr during study period (SCr values of each group at R20 [Week 20 of the run-in period] were set as 100 %)
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Trial registration
NCT02480751. June 21, 2015.
Results
Patient disposition
The trial began on October 24, 2005 (the date the first
consent was obtained) and was completed on May 20,
2008 (the last follow-up date of the final patient).
A summary of the patient disposition is described in
Fig. 3. Written informed consents were obtained from a
total of 431 patients, 11 of whom did not meet the criteria
on pre-registration and a total of 420 patients were pre-
registered. Of these 420 patients, 29 dropped out before
the start of the run-in period and a further 278 patients
were withdrawn during the run-in period or at the regis-
tration. A total of 113 patients were therefore registered,
of which one patient, who mistakenly took the run-in
period medication and did not take the study drug for the
treatment period after the registration, was excluded from
the study. As a result, the study drugs were administered
to a final total of 112 patients (35 patients in the placebo
group, 36 patients in the 120 μg group and 41 patients in
the 240 μg group) in a double-blind manner. Most of 238
patients who did not meet the inclusion/exclusion criteria
before registration were excluded because their renal
failure progressed at a slower rate during the run-in
period, represented by a 1/SCr versus time slope of ≤
−0.005 dL/mg over 4 weeks.
Analysis sets
Ten patients whose SCr values measured less than three
points after Week 4 of the treatment period were excluded
from 112 patients randomized. As a result, 102 patients
(34 patients in the placebo group, 32 patients in the
120 μg group and 36 patients in the 240 μg group) were
included in the full analysis set (FAS). From FAS, four
patients were excluded whose SCr values measured after
Week 4 of the treatment period were less than 5 points.
The remaining patients constituted the per protocol set
(PPS). PPS therefore consisted of 98 patients (34 patients
in the placebo group, 29 patients in the 120 μg group and
35 patients in the 240 μg group). The safety analysis set
consisted of 112 patients (35 patients in the placebo
group, 36 patients in the 120 μg group and 41 patients in
the 240 μg group), who received the study drug for the
treatment period.
Demographic and other baseline characteristics of pa-
tients in the FAS are presented in Table 2. Baseline char-
acteristics of patients were not significantly different
Table 4 Difference in the 1/SCr versus time slope between run-in period (R0 ~ R20), and Treatment period (W4 ~W28) analyzed by
the ANCOVA model: comparison of the TRK-100STP groups versus placebo
Treatment group No. of patients Least square mean of the change in
the 1/SCr slope




Point estimate 95 % CI Point estimate 95 % CI (−1,0,1)
Placebo 34 0.00516 [0.00187, 0.00845] ― ―
120 μg 32 0.01026 [0.00682, 0.01369] 0.00510 [0.00031, 0.00989]
240 μg 36 0.00798 [0.00478, 0.01118] 0.00282 [−0.00175, 0.00740] 0.2234
a(120 μg group or 240 μg group) – (placebo group)
1/Scr versus time slope during the run-in period as the covariate
Fig. 5 Primary endpoint: Least square mean of the change in the 1/SCr time slope
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among the treatment groups. It is noteworthy that 69 % to
81 % of patients were taking ARB in each group.
Changes in SCr
Figure 4 illustrates the changes in SCr through the study
periods when SCr values of each group at R20 were set
at 100 %. The SCr values in all three groups increased
during the run-in and treatment periods, and increases
in SCr values in the treatment period tends to be sup-
pressed in the two TRK-100STP groups.
Efficacy
As the primary analysis set is also the FAS, the data and
the results of evaluation are described based on the FAS,
whilst the efficacy analysis was performed in both the
FAS and PPS.
(a) Primary endpoint
The difference in the 1/SCr versus time slope between
the run-in period (R0 ~ R20) and the treatment period
(W4 ~W28)
As shown in Table 3 and Fig. 5, compared with the
run-in period, a slight improvement in the 1/SCr versus
time slope was observed during the treatment period in
all treatment groups; this tendency was clearly observed
in patients of the TRK-100STP 120 μg group.
Table 4 shows the result of ANCOVA with the 1/SCr
versus time slope during the run-in period as the covari-
ate. No statistically significant difference was observed
between the 240 μg group and the placebo group when
the ANCOVA was performed with the contrast coeffi-
cients of [−1, 0, 1] for [the placebo group, the 120 μg
group, and the 240 μg group] (P = 0.2234).
(b) Secondary endpoints
The difference in the 1/SCr versus time slope between
the run-in period (R0 ~ R20) and the treatment period
(W0 ~W28)
The least square mean of the difference in the 1/SCr
versus time slope [95 % CI] was 0.00590 dL/mg over 4
weeks [0.00308, 0.00873] in the placebo group, 0.01065 dL/
mg over 4 weeks [0.00769, 0.01360] in the TRK-100STP
120 μg group and 0.00801 dL/mg over 4 weeks [0.00525,
0.01076] in the 240 μg group. Moreover, ANCOVA was
performed on the same model as the primary endpoint with
the contrast coefficients of [−1, 0, 1], [−1, 1, 0], [−1, −1, 2],
and [−2, 1, 1] for the placebo group, the 120 μg group,
and the 240 μg group, respectively. The results of
ANCOVA with contrast coefficients of [−1, 0, 1], [−1, 1, 0],
[−1, −1, 2] and [−2, 1, 1] were P = 0.2912, P = 0.0244,
P = 0.8764 and P = 0.0534, respectively. Thus the 120 μg
Fig. 6 Mean ± SD of ratio of SCr (final evaluation point/W0 [week 0 of the treatment period]): As shown in Table 5, both the 120 μg and the
240 μg groups showed an inhibition of the increase in SCr ratios as compared with the placebo group (P = 0.0309, 0.0204, respectively), assessed
by ANCOVA with the SCr (R20) as covariate
Table 5 Ratio of SCr [the final evaluation pointa/W0 (week 0 of

















Placebo 34 1.169 0.032 – – –
120 μg 32 1.069 0.033 0.100 0.045 0.0309
240 μg 36 1.064 0.031 0.105 0.044 0.0204
aAt Week 28 of the treatment period or when treatment was discontinued
*ANCOVA with baseline (SCr(R20)) as covariate
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group showed a significant amelioration compared with the
placebo group (contrast coefficients: [−1, 1, 0]: P = 0.0244).
Changes in CCr
The difference in the change of CCr in urinalysis with
24-hour pooled urine sample (the change in the treatment
period [the final evaluation point – R20]) was 1.08 ±
9.35 mL/min in the placebo group (mean ± SD), 6.16 ±
11.22 mL/min in the TRK-100STP 120 μg group and
3.94 ± 7.80 mL/min in the 240 μg group. Both TRK-
100STP groups therefore showed a tendency of inhibit-
ing the decline in CCr as compared with the placebo
group (P = 0.0551, P = 0.1800: t-test). When CCr was cal-
culated with the Cockcroft-Gault equation, the change in
the treatment period (the final evaluation point – R20)
was 2.03 ± 5.98 mL/min in the placebo group (mean ±
SD), 3.93 ± 5.30 mL/min in the TRK-100STP 120 μg group
and 3.77 ± 5.06 mL/min in the 240 μg group. Both TRK-
100STP groups therefore showed a tendency of inhibiting
the decline in CCr as compared with the placebo group
(P = 0.1771, P = 0.1917: t-test).
Changes in urinary protein excretion
The change in urinary protein excretion (the final
evaluation point – R20) was 121.59 ± 715.60 mg/day in
the placebo group, 241.68 ± 849.23 mg/day in the TRK-
100STP 120 μg group and 280.38 ± 817.97 mg/day in
240 μg group. It was shown that the observed change in
the urinary protein excretion in the 120 μg and 240 μg
groups (versus the placebo group) was small relative to
the standard deviation, and both TRK-100STP groups
showed no significant difference compared to the placebo
group (P = 0.5457, P = 0.4056: t-test).
Ratio of SCr
The ratio of SCr (the final evaluation point/R20) was
1.14 ± 0.27 in the placebo group, 1.06 ± 0.20 in the TRK-
100STP 120 μg group and 1.06 ± 0.13 in the 240 μg
group. Although both TRK-100STP groups did not show
any significant inhibition, they showed a tendency of
inhibiting the increase in SCr as compared with the
placebo group (P = 0.1379, P = 0.0942: t-test).
Changes in serum cystatin C
The difference in the change in serum cystatin C (the
change in the treatment period [the final evaluation
point – R20] – the change in the Run-in period [R20 –
R0]) was 0.155 ± 0.448 mg/L in the placebo group,
0.006 ± 0.377 mg/L in the TRK-100STP 120 μg group,
and −0.023 ± 0.645 mg/L in the 240 μg group. Both
TRK-100STP groups therefore showed a tendency of
inhibiting the increase in serum cystatin C as compared
versus the placebo group (P = 0.1588, P = 0.1973: t-test).
Fig. 7 Mean ± SD of changes in serum cystatin C (final evaluation point – R20): As shown in Table 6, the 120 μg group showed a tendency and
the 240 μg group showed significant inhibition of the increase in change in serum cystatin C as compared with the placebo group (P = 0.0928,
0.0285, respectively), assessed by ANCOVA with the SCr (R20) as covariate
Table 6 Changes in serum cystatin C [the final evaluation
pointa-R20 (week 20 of the Run-in period)] comparison of





















Placebo 32 0.253 0.065 ― ― ―
120 μg 31 0.097 0.066 0.157 0.092 0.0928
240 μg 35 0.052 0.063 0.201 0.090 0.0285
aAt Week 28 of the treatment period or when treatment was discontinued
bDifferent from FAS because some patients lacked value of cystatin C
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(c) Post hoc analysis
Ratio of SCr (final evaluation point/W0)
As shown in Table 5 and Fig. 6, both the 120 μg and
the 240 μg groups showed a significant inhibition of the
increase in SCr ratios as compared with the placebo
group.
Change in serum cystatin C in treatment period (final
evaluation point – R20)
As shown in Table 6 and Fig. 7, the 120 μg group
showed a tendency and the 240 μg groups showed signifi-
cant inhibition of the increase in change in serum cystatin
C as compared with the placebo group.
Ratio of eGFR
As shown in Table 7, the 240 μg group showed a tendency
and the 120 μg groups showed significant inhibition of the
decrease in eGFR ratios as compared with the placebo
group.
Safety and tolerability
The safety analysis was conducted based on any AEs re-
ported during the study period. The incidence of AEs are
summarized in Table 8. Two death were observed in this
study; they occurred during the run-in period and so any
causal relationships with the study drug was excluded.
The incidence of ADRs are summarized in Table 9. All
of these ADRs cases were mild to moderate in severity,
and recovered without treatment. Two serious adverse
drug reactions (SADR) of cardiac failure and acute myo-
cardial infarction were observed in the 120 μg group
after randomization and both patients recovered.
The AEs and ADRs that occurred at an incidence of 5 %
or more are summarized in Table 10. The severity of
headache in ADR was as follows: moderate headache was
reported in 1 patient in the 240 μg group; mild headache
was reported in 1 patient in the 120 μg group, and 5 pa-
tients in the 240 μg group. All of these patients recovered
without treatment. For clinical laboratory tests, vital signs,
body weight and 12-lead ECG, no specific concerns were
observed. TRK-100STP did not have significant effect on
blood pressure at any dose, as detailed in Table 11.
Discussion
This is the first randomized, double-blind, placebo con-
trolled comparative trial of TRK-100STP to investigate
the possible therapeutic dose of TRK-100STP in CKD
patients with a primary disease of glomerular disease or
nephrosclerosis.
In the FAS, statistical superiority of the 240 μg group
over the placebo could not be confirmed by the primary
endpoint, and so the putative recommended dose could
not be clearly determined. One of the reasons why statisti-
cally significant superiority could not be confirmed was
the trial lost statistical power due to the fact that more
patients than had been expected were withdrawn from the
study during the run-in period. As we needed to consider
the feasibility of study completion, we could not secure
the sufficient number of patients for analysis.
This is considered to be because the pace at which the
decline in renal function became slower during the run-
in period. As shown in Table 3, 1/SCr versus time slope
in the treatment period was ameliorated even in the pla-
cebo group. In this trial, the CKD patients who pro-
gressed and whose 1/SCr versus time slopes were ≤
−0.005 dL/mg over 4 weeks were selected at the start of
the treatment period. As a result, the number of patients
to be enrolled was reduced to about 1/3 of patients who
had been screened. It is thought that such selection of
patients also led to the regression toward the mean in all
groups. This amelioration in the 1/SCr versus time slope
in the placebo group may have made it difficult to detect
the difference between the placebo group and the
240 μg group in terms of the primary endpoint. How-
ever, our trial showed, for the first time, that TRK-
100STP might prevent the decline of renal function.
Table 8 Summary of the incidence of adverse events
Parameter 120 μg 240 μg Placebo
Number of patients evaluated 36 41 35
Number of patients who experienced adverse events 27 (75.0 %) 36 (87.8 %) 28 (80.0 %)
Number of patients who experienced serious adverse events 3 (8.3 %) 4 (9.8 %) 1 (2.9 %)
Number of patients who discontinued the study treatment due to adverse events 4 (11.1 %) 7 (17.1 %) 0 (0.0 %)
Number of patients who interrupted the study treatment due to adverse events 0 (0.0 %) 2 (4.9 %) 0 (0.0 %)
(): Incidence rate
Table 7 Change in eGFR [the final evaluation pointa/W0 (week




















Placebo 34 0.877 0.025 ― ― ―
120 μg 32 0.952 0.026 0.075 0.036 0.0365
240 μg 36 0.942 0.024 0.065 0.035 0.0628
aAt Week 28 of the treatment period or when treatment was discontinued
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This conclusion was supported by the following facts:
both active study drug treatment groups exhibited better
efficacy than the placebo group, and the efficacy was
particularly high in the 120 μg group on the primary
endpoint. In the secondary endpoint analysis, both TRK-
100STP groups showed improvements on each of the renal
filtration function parameters evaluated (1/SCr versus time
slope, change in the CCr, ratio of SCr, and change in serum
cystatin C). Among them, a significant improvement was
observed in the slope for 1/SCr versus time when contrast
coefficients [−1, 1, 0] were used, suggesting a valid hypoth-
esis that the improvement in 120 μg group was remarkable.
In addition, in the post-hoc analysis, a significant improve-
ment in the ratio of SCr was achieved in the 120 μg group
as well as in the 240 μg group. The difference in cystatin C
levels in the treatment period also improved in the 240 μg
group. Regarding the eGFR ratio, a significant improve-
ment was observed only in the 120 μg group.
Significant effects on blood pressure or urinary protein
levels were not observed in this study, and thus the mech-
anisms of action of BPS are thought to be different from
those of existing agents such as ACEIs and ARBs. Since
the majority of patients in this study was taking ACEIs
and/or ARBs, TRK-100STP may be a useful for treatment
of CKD patients in combination with ACEIs or ARBs.
TRK-100STP was considered to be well tolerated. Most of
the AEs observed in this study were similar types of the
events caused by prostacyclin and its analogue.
Several important limitations to this study are appar-
ent: as the treatment period was comparatively short
(28 weeks) for evaluating the decrease in the renal func-
tion, the enrollment to the trial was restricted to those
patients whose renal function had progressively declined.
In addition, no dialysis or doubling of SCr was observed
during the study period so that its efficacy on the renal
composite endpoint including dialysis was unclear. Fur-
ther evaluation in a longer study period will therefore be
necessary in future.
Based on the findings of this trial, we have further
been conducting a phase IIb/III trial, CASSIOPEIR (CRF
Asian Study with Oral PGI2 derivative for Evaluating
Improvement of Renal function) [42]. This new trial will
enroll patients who have more severe disease than those
enrolled in this trial in order to ensure that a sufficient
Table 10 Adverse events and adverse drug reactions with an incidence of 5 % or more
Adverse Events
120 μg 240 μg Placebo
Headache 5 (13.9 %) Nasopharyngitis 11 (26.8 %) Nasopharyngitis 8 (22.9 %)
Nasopharyngitis 4 (11.1 %) Headache 7 (17.1 %) Pruritus 3 (8.6 %)
Back pain 3 (8.3 %) Diarrhea 5 (12.2 %) Fever 3 (8.6 %)
Hyperkalemia 2 (5.6 %) Malaise 3 (7.3 %) Hyperkalemia 3 (8.6 %)
Dizziness 2 (5.6 %) Influenza 2 (5.7 %)
Hypertension 2 (5.6 %) Hyperkalemia 2 (5.7 %)
Upper respiratory tract inflammation 2 (5.6 %) Muscle Spasm 2 (5.7 %)
Diarrhea 2 (5.6 %) Genital Bleeding 2 (5.7 %)
Vomiting 2 (5.6 %)
Arthralgia 2 (5.6 %)
Adverse drug reactions
120 μg 240 μg Placebo
Hypertension 2 (5.6 %) Headache 6 (14.6 %) Genital Bleeding 2 (5.7 %)
Malaise 3 (7.3 %)
(): Incidence rate
Table 9 Summary of adverse drug reaction incidence
Parameter 120 μg 240 μg Placebo
Number of patients evaluated 36 41 35
Number of patients who experienced ADR 7 (19.4 %) 13 (31.7 %) 5 (14.3 %)
Number of patients who experienced serious ADR 2 (5.6 %) 0 (0.0 %) 0 (0.0 %)
Number of patients who discontinued the study treatment due to ADR 3 (8.3 %) 5 (12.2 %) 0 (0.0 %)
Number of patients who interrupted the study treatment due to ADR 0 (0.0 %) 1 (2.4 %) 0 (0.0 %)
(): Incidence rate
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number of clinical events can be observed within a des-
ignated time period, using renal composite endpoints to
evaluate treatment outcome. This trial will also be dose-
finding as it utilizes the same two doses as used in this
study. The trial is being conducted in seven Asian coun-
tries, including Japan.
Conclusions
Although this randomized, placebo-controlled, double-
blind, comparative trial failed to meet the primary endpoint
to determine the recommended dose for the treatment of
patients with CKD with primary glomerular disease or
nephrosclerosis, it shows for the first time, that TRK-
100STP might potentially prevent the decline in renal func-
tion of such patients, independent of blood pressure or
urinary protein levels. These findings have helped in the
design and conduct of the ongoing phase IIb/III trial,
CASSIOPEIR.
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